Home About Titan Pharmaceuticals Products Press Releases Financials Resources: Scientific Articles and Presentations Contact Us

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Titan Pharmaceuticals Second Quarter 2015 Financial Results

MONDAY, AUGUST 17, 2015 - 10:00 am PT | 1:00 pm ET

Participant Toll Free: 888-417-8516 | Participant Passcode: 1862785
THE EVENT/REGISTRATION PAGE URL FOR THE WEBCAST IS: http://www.visualwebcaster.com/event.asp?id=102744

 

Titan Pharmaceuticals Latest Press Releases

SOUTH SAN FRANCISCO, CA – August 13, 2015Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term drug delivery technology, today reported financial results for the second quarter ended June 30, 2015.

 

Total revenue in the second quarter of 2015 was approximately $0.8 million compared with revenue of approximately $0.9 million in the second quarter of 2014. Second quarter 2015 and 2014 revenues consisted entirely of license revenue and reflect the amortization of the upfront license fee received from development and commercialization partner Braeburn Pharmaceuticals in December 2012.

Read Press Release » »

SOUTH SAN FRANCISCO, CA – August 11, 2015 – Titan Pharmaceuticals, Inc. (OTCQB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Monday, Aug. 17, 2015 to discuss the company’s financial results as of June 30, 2015. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the second quarter will be included in a press release to be issued prior to the call.

Read Press Release » »

South San Francisco, CA – June 17, 2015Titan Pharmaceuticals, Inc. (OTCQB: TTNP) today presented nonclinical data at the 19th International Congress of Parkinson's Disease and Movement Disorders in San Diego demonstrating the potential of Titan's ProNeura™ long-term, continuous drug delivery platform in the treatment of Parkinson's disease. ProNeura-based subdermal implants containing the dopamine agonist ropinirole were first characterized for pharmacokinetics of drug release in rats followed by an evaluation of motor function and onset of treatment-related dyskinesias in an implant dose-escalating study in the Parkinsonian monkey model.

Read Press Release » »

South San Francisco, CA – June 10, 2015Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term drug delivery technology, announced today that President Sunil Bhonsle will present at the BIO International Convention 2015 being held June 16-18 at the Pennsylvania Convention Center in Philadelphia. The presentation will take place on Tuesday, June 16 at 4:15 p.m. in Theater 3.

Read Press Release » »

Read more Titan Pharmaceuticals Press Releases

Probuphine®

Probuphine is Titan’s novel subdermal implant formulation designed using its ProNeura technology to deliver six months of buprenorphine hydrochloride (“buprenorphine”) following a single treatment. Probuphine is being developed for the treatment of opioid dependence...

 

Read More... »»

 

Probuphine® Program Update

 

April. 15, 2015
Phase 3 Study Completion on Schedule for Late Q2, 2015

Titan announced completion of patient enrollment in the Phase 3 study of Probuphine®, the company’s investigational subdermal implant for the maintenance treatment of opioid dependence, on Nov. 30. The study is expected to be completed on schedule by the end of the second quarter ...

 

Read More... »»

 

Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of central nervous system (“CNS”) disorders.

Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.5 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011.  This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication...

 

Read more... » »